Lantheus Holdings, Inc.: Business Overview, Financials & Competitive Analysis
Lantheus Holdings, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Lantheus is well-positioned to capture oncology imaging growth with strong pipeline and strategic focus, though leadership change and reimbursement challenges warrant careful monitoring. Lantheus demonstrates strong market positioning as a leading radiopharmaceutical company with robust revenue growth and strategic portfolio optimization through divestitures and acquisitions. However, recent leadership transition.
What is Lantheus Holdings, Inc.'s industry? Lantheus Holdings, Inc. (lantheus.com) operates in Radiopharmaceuticals & Diagnostic Imaging. AskCyborg classifies Lantheus Holdings, Inc. under Radiopharmaceuticals & Diagnostic Imaging in its company registry.
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. The company develops, manufactur...
Cyborg Score thesis
Lantheus is well-positioned to capture oncology imaging growth with strong pipeline and strategic focus, though leadership change...
Read the full analyst-debate transcript →Get the Latest Lantheus Holdings, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeLantheus Holdings, Inc. Overview
Pro stress-test →Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. The company develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Strategic Profile
Pro stress-test →Lantheus completed the sale of its SPECT business to SHINE Technologies in January 2026, transferring SPECT diagnostic agents and related operations. The company closed the acquisition of Life Molecular Imaging in July 2025 and repurchased $100M of common stock in Q3. Updated FY2025 guidance shows $1.49B–$1.51B revenue and $5.50–$5.65 adjusted EPS.
Competitive Landscape
Pro stress-test →Lantheus classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic. The company competes in the nuclear medicine and molecular imaging space against larger diversified healthcare companies and specialized diagnostic imaging firms. Key competitive advantages include focus on radiopharmaceuticals, advanced PET imaging pipeline, and strategic portfolio optimization.
Industry Context
Lantheus Holdings, Inc. operates in Radiopharmaceuticals & Diagnostic Imaging.
Key facts
Founded: 1956 · Headquarters: Bedford, Massachusetts, US · Employees: ~2,000 · Revenue: $1.53B · Market cap: ~$5.5B